
Patients with aNSCLC diagnosis on or after 01 Jan 2011, diagnosis of non-squamous histology any time during baseline, and 18 to 75 years old at index date
N=27,937
Patients who did not have a baseline ECOG performance status of 0-1
N=11,171
Patients who had a baseline ECOG performance status of 0 or 1
N=16,766
Patients who did not initiate 1L pembrolizumab + pemetrexed + platinum
N=14,268
Patients who initiated 1L pembrolizumab + pemetrexed + platinum 10May2017-31Mar2021
N=2,498
Patients with unknown PD-LI expression
N=524
Patients with known tumor PD-L1 expression level (any time)
N=1,974
Patients with <3 months follow-up after index date[a]
N=480
Patients with at least 3 months follow up after index date[a]
N=1,494
Patients with positive EGFR or ALK
N=105
Patients without evidence of positive EGFR or ALK[b]
N=1,389
Patients with evidence of inadequate hematopoietic, hepatic, renal, and coagulation function at baseline
N=213
Patients without evidence of inadequate hematopoietic, hepatic, renal, and coagulation function at baseline
N=1,176
Patients with evidence of baseline CNS metastases, and no previous ICI treatment
N=114
Patients without evidence of baseline CNS metastases and previous ICI treatment
N=1,062
Patients with evidence of systemic glucocorticoid therapy and anti-infective therapy (antibiotics, antivirals, antifungals) within 7 days prior to index date
N=378
Patients without evidence of systemic glucocorticoid therapy and anti-infective therapy (antibiotics, antivirals, antifungals) within 7 days prior to index date
N=684
Patients without evidence of structured activity in the first 90 days following advanced NSCLC diagnosis date
N=16
Patients with evidence of structured activity in the first 90 days following advanced NSCLC diagnosis date
N=668
Patients with evidence of another primary cancer, except basal cell or non-melanoma skin cancer
N=91
Target US population
N=577